Adocia SAS (ADOC):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Adocia SAS (ADOC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8029)・商品コード:DATA904C8029
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:43
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Adocia SAS (Adocia) is a biotechnology company that discovers and develops therapeutic proteins. The company provides products such as formulation of PDGF-BB for the treatment of diabetic foot ulcers. It offers novel insulin formulations for the treatment of diabetes and BioChaperone Lispro U100 and U200, ultra-rapid formulations of insulin analogs. Adocia develops HinsBet U100, a formulation of human insulin and a combination of slow-acting insulin glargine and rapid-acting insulin lispro. The company also develops a formulation of human insulin, HinsBet U500. Its BioChaperone is a proprietary technological platform developed from polymers, oligomers and small organic compounds, and others. It operates in the US and France. Adocia is headquartered in Lyon, France.

Adocia SAS (ADOC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 9
Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adocia SAS, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 11
Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 12
Equity Offering 13
Adocia Raises USD35 Million in Private Placement of Shares 13
Adocia Completes Partial Exercise Of Underwriter’s Option For IPO For US$36 Million 15
Adocia SAS – Key Competitors 16
Adocia SAS – Key Employees 17
Adocia SAS – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Jul 18, 2018: Adocia presents first half 2018 financial results 19
Apr 16, 2018: Adocia Announces First Quarter 2018 Financial Results 21
Mar 19, 2018: ADOCIA Reports Financial Results For 2017 22
Oct 11, 2017: Adocia announces financial results for the third quarter 2017 24
Jul 19, 2017: Adocia Presents First Half 2017 Financial Results 26
Mar 07, 2017: ADOCIA announced its financial results for 2016 and its perspectives for 2017 28
Feb 14, 2017: Adocia announces its revenue and cash position for 2016 30
Corporate Communications 31
Jul 26, 2017: Adocia Announces Appointment of Dr. Stanislav Glezer as Chief Medical Officer 31
Legal and Regulatory 32
Oct 11, 2018: Adocia Informs about a Civil Action filed by Eli Lilly 32
Aug 30, 2018: Adocia announces update to second arbitration against Eli Lilly & Company 33
Aug 20, 2018: American Arbitration Association Panel Finds in Favor of Adocia in First Phase of Arbitration against Eli Lilly 34
Feb 06, 2018: Adocia Files Additional Arbitration Claims Against Eli Lilly & Company 35
Product News 36
01/05/2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes 36
Jan 04, 2018: Adocia Announces Expanded BioChaperone Product Portfolio beyond Diabetes 37
Clinical Trials 38
Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes 38
Jun 01, 2017: Adocia Launches First-in-Man Clinical Study of BioChaperone Glucagon BioChaperone Glucagon, a ready-to-use stable aqueous formulat 40
Other Significant Developments 41
Jan 19, 2017: Adocia announces the transformation of its business model to increase the value of its projects 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Adocia SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adocia SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adocia SAS, Deals By Therapy Area, 2012 to YTD 2018 9
Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10
Adocia SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tonghua Dongbao Pharma Enters into Licensing Agreement with Adocia 12
Adocia Enters into Licensing Agreement with Centre National de la Recherche Scientifique 13
Adocia Raises USD35 Million in Private Placement of Shares 14
Adocia Completes Partial Exercise Of Underwriter’s Option For IPO For US$36 Million 16
Adocia SAS, Key Competitors 17
Adocia SAS, Key Employees 18
Adocia SAS, Subsidiaries 19

List of Figures
Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adocia SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adocia SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adocia SAS, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Adocia SAS (ADOC):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8029)販売に関する免責事項を必ずご確認ください。
★調査レポート[Adocia SAS (ADOC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆